# US 2004/0072166 A1 · HURP gene as a molecular marker for bladder cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072166 A1
- Document ID: US20040072166A1
- Status: Published application
- Kind: A1
- Application number: 10/259,326
- Filed: 2002-09-30
- Published: 2004-04-15
- Earliest claimed: 2002-09-30
- Assignees: Chi Mei Foundation Medical Center
- Inventors: Allen W. Chiu; Yu-Lun Huang; Chen-Kung Chou
- Web page: https://patentgrep.com/patent/US20040072166A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Hepatoma up-regulated protein (HURP) gene serves as a useful molecular marker in the detection, preliminary screening and monitoring of bladder cancer in a human subject. A method for the detection of bladder cancer, in particular transitional cell carcinoma (TCC) of the bladder, in a human subject is disclosed, in which the detected expression of the human HURP gene in a sample taken from a subject suspected to have bladder cancer is indicative of the presence of the bladder cancer. The present invention further provides a non-invasive method for the detection, preliminary screening or monitoring of urinary TCC in a suspected subject, in which a urine sample taken from the subject is analyzed to determine an expression of the human HURP gene, the presence of which is indicative of the presence of urinary TCC.

## Claims

### Claim 1

A method for the detection of bladder cancer in a human subject, comprising the steps of:
(1) obtaining a biological sample from a subject suspected to have bladder cancer; and
(2) detecting the expression of a human HURP gene in said sample, the detected expression of the human HURP gene being indicative of the presence of the bladder cancer.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bladder cancer is transitional cell carcinoma (TCC) of the bladder.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the biological sample comprises cells selected from the group consisting of urothelial cancer cells, bladder cancer cells or a combination of both.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the biological sample is selected from the group consisting of urine, urothelial biopsy, blood, plasma and serum.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the biological sample is urine.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the human HURP gene has a nucleotide sequence as set forth in SEQ ID NO:1.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the detection of the expression of the human HURP gene is conducted by detecting the presence of mRNA transcript of the human HURP gene in the biological sample.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the detection of the presence of mRNA transcript of the human HURP gene is conducted using at least one of the following methodologies: hybridization, cycling probe reaction, polymerase chain reaction (PCR), nested PCR, reverse-transcriptase polymerase chain reaction (RT-PCR), multiplex PCR polymerase chain reaction-single strand conformation polymorphism, ligase chain reaction (LCR), restriction fragments length polymorphism nucleic acid sequence-based amplification (NASBA), and transcription-mediated amplification (TMA).

### Claim 9 (depends on 7)

The method according to claim 7, wherein the detection of the presence of mRNA transcript of the human HURP gene is conducted using RT-PCR.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the detection of the presence of mRNA transcript of the human HURP gene is conducted by:
(a) extracting total RNA from the biological sample;
(b) subjecting the extracted RNA from step (a) to a reverse transcriptase-polymerase chain reaction (RT-PCR) treatment using at least a primer pair of a forward primer and a reverse primer, each primer having a nucleotide sequence that hybridizes to at least 13 nucleotides of a human HURP gene having a nucleotide sequence corresponding to SEQ ID NO:1; and
(c) detecting whether or not a RT-PCR product having a nucleotide sequence identical or complementary to a part of the nucleotide sequence of the human HURP gene has been produced from the RT-PCR treatment of step (b), the presence of said RT-PCR product being indicative of the presence of the bladder cancer.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the at least a primer pair used in step (b) comprises a forward primer having a nucleotide sequence selected from the sequences as set forth in SEQ ID NO:2 and SEQ ID NO:4, and a reverse primer having a nucleotide sequence selected from the sequences as set forth In SEQ ID NO:3 and SEQ ID NO:5.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the at least a primer pair used in step (b) comprises a forward primer having a nucleotide sequence corresponding to SEQ ID NO:4 and a reverse primer having a nucleotide sequence corresponding to SEQ ID NO:5.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the RT-PCR treatment in step (b) includes a first amplification reaction using a first primer pair comprising a first forward primer having a nucleotide sequence corresponding to SEQ ID NO:2 and a first reverse primer having a nucleotide sequence corresponding to SEQ ID NO:3, and a second amplification reaction using a second primer pair comprising a second forward primer having a nucleotide sequence corresponding to SEQ ID NO:4 and a second reverse primer having a nucleotide sequence corresponding to SEQ ID NO:5.

### Claim 14

A method for monitoring bladder cancer in a human subject, comprising the steps of:
(1′) periodically obtaining a biological sample from a subject suspected to have bladder cancer; and
(2′) detecting the expression of a human HURP gene in said sample, the detected expression of the human HURP gene being indicative of the presence of the bladder cancer.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the bladder cancer is transitional cell carcinoma (TCC) of the bladder.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the biological sample comprises cells selected from the group consisting of urothelial cancer cells, bladder cancer cells or a combination of both.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the biological sample is selected from the group consisting of urine, urothelial biopsy, blood, plasma and serum.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the biological sample is urine.

### Claim 19 (depends on 14)

The method according to claim 14, wherein the human HURP gene has a nucleotide sequence as set forth in SEQ ID NO:1.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the detection of the expression of the human HURP gene is conducted by detecting the presence of mRNA transcript of the human HURP gene in the biological sample.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the detection of the presence of mRNA transcript of the human HURP gene is conducted using at least one of the following methodologies: hybridization, cycling probe reaction, polymerase chain reaction (PCR), nested PCR, reverse-transcriptase polymerase chain reaction (RT-PCR), multiplex PCR polymerase chain reaction-single strand conformation polymorphism, ligase chain reaction (LCR), restriction fragments length polymorphism nucleic acid sequence-based amplification (NASBA), and transcription-mediated amplification (TMA).

### Claim 22 (depends on 20)

The method according to claim 20, wherein the detection of the presence of mRNA transcript of the human HURP gene is conducted using RT-PCR.

### Claim 23 (depends on 20)

The method according to claim 20, wherein the detection of the presence of mRNA transcript of the human HURP gene is conducted by:
(a′) extracting total RNA from the biological sample;
(b′) subjecting the extracted RNA from step (a′) to a reverse transcriptase-polymerase chain reaction (RT-PCR) treatment using at least a primer pair of a forward primer and a reverse primer, each primer having a nucleotide sequence that hybridizes to at least 13 nucleotides of a human HURP gene having a nucleotide sequence corresponding to SEO ID NO:1; and
(c′) detecting whether or not a RT-PCT product having a nucleotide sequence identical or complementary to a part of the nucleotide sequence of the human HURP gene has been produced from the RT-PCR treatment of step (b′), the presence of said RT-PCR product being indicative of the presence of the bladder cancer.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the at least a primer pair used in step (b′) comprises a forward primer having a nucleotide sequence selected from the sequences as set forth in SEQ ID NO:2 and SEQ ID NO:4 and a reverse primer having a nucleotide sequence selected from the sequences as set forth in SEQ ID NO:3 and SEQ ID NO:5.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the at least a primer pair used in step (b′) comprises a forward primer having a nucleotide sequence corresponding to SEQ ID NO:4 and a reverse primer having a nucleotide sequence corresponding to SEQ ID NO:5.

### Claim 26 (depends on 23)

The method according to claim 23, wherein the RT-PCR treatment in step (b′) includes a first amplification reaction using a first primer pair comprising a first forward primer having a nucleotide sequence corresponding to SEQ ID NO:2 and a first reverse primer having a nucleotide sequence corresponding to SEQ ID NO:3, and a second amplification reaction using a second primer pair comprising a second forward primer having a nucleotide sequence corresponding to SEQ ID NO:4 and a second reverse primer having a nucleotide sequence corresponding to SEQ ID NO:5.

### Claim 27

A DNA sequence having a nucleotide sequence selected from the sequences as set forth in SEQ ID NOs:2 to 5.

### Claim 28

A primer set for the detection of bladder cancer in a human subject, comprising a forward primer having a nucleotide sequence selected from the sequences as set forth in SEQ ID NO:2 and SEQ ID NO:4, and a reverse primer having a nucleotide sequence selected from the sequences as set forth in SEQ ID NO:3 and SEQ ID NO:5.

### Claim 29 (depends on 28)

A primer set of claim 28, wherein the forward primer has the nucleotide sequence as set forth in SEQ ID NO:2.

### Claim 30 (depends on 28)

A primer set of claim 28, wherein the forward primer has the nucleotide sequence as set forth in SEQ ID NO:4.

### Claim 31 (depends on 28)

A primer set of claim 28, wherein the reverse primer has the nucleotide sequence as set forth in SEQ ID NO:3.

### Claim 32 (depends on 28)

A primer set of claim 28, wherein the reverse primer has the nucleotide sequence as set forth in SEQ ID NO:5.

### Claim 33

A diagnosis kit for the detection of bladder cancer in a human subject, containing at least a primer pair of a forward primer and a reverse primer, each primer having a nucleotide sequence that hybridizes to at least 13 nucleotides of a human HURP gene having a nucleotide sequence corresponding to SEQ ID NO:1.

### Claim 34 (depends on 34)

The diagnosis kit according to claim 34, containing a first primer pair comprising a first forward primer having a nucleotide sequence corresponding to SEQ ID NO:2 and a first reverse primer having a nucleotide sequence corresponding to SEQ ID NO:3, and a second primer pair comprising a second forward primer having a nucleotide sequence corresponding to SEQ ID NO:4 and a second reverse primer having a nucleotide sequence corresponding to SEQ ID NO:5.
